MOLN
Strong SellSinkerMolecular Partners AG · Healthcare · Switzerland · $172M · Avg Vol: $5K/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
19
StockRankGet insider-trade alerts
QualityQuality
21
ValueValue
31
MomentumMomentum
50
P/E (TTM)
—
peers 29.9x
ROE
-62.0%
peers 11.4%
D/E
0.1x
peers 0.4x
Dividend %
—
trailing yield
ABOUT MOLECULAR PARTNERS AG
Read
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 230.7M | 8.6M | 6.0M | 0 | -83.8% | — | 6.8M | 37.3M | 83.5% |
| EPS | 4.42 | -2.30 | -1.93 | -2.01 | — | -1.65 | -1.35 | -0.17 | — |
| Shares | 36.0M | 32.9M | 36.9M | 37.4M | +3.8% | 38.3M | — | — | — |
| Debt | 5.9M | 4.4M | 3.0M | 4.4M | -9.1% | 3.7M | — | — | — |
| Equity | 286.2M | 214.7M | 172.3M | 97.8M | -30.1% | — | — | — | — |
| Op CF | 144.3M | -71.8M | -72.1M | -62.4M | — | -55.9M | — | — | — |
| Inv CF | -123.0M | 54.3M | 49.3M | 88.3M | — | — | — | — | — |
| Fin CF | -1.9M | -1.4M | 17.6M | -1.4M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+4.0%
SMA 50SMA 200
Close
$4.21
RSI (14)
41.9
52W High
$5.36
From 52W High
0.8%
SCORE BREAKDOWN
Quality
21
ROIC
-63.7%11.8
ROE
-62.0%15.3
GP/Assets
-34.2%2.5
Op. Margin
0.0%38.6
FCF/Assets
-50.9%6.5
Piotroski
12.4
Int. Cover
-50.0x5.9
D/E Ratio
0.05x71.0
Current Ratio
7.27x81.8
Value
31
P/E (TTM)
—N/A
EV/EBITDA
-1.6x25.0
P/FCF
—N/A
P/B
1.9x64.2
P/S
—N/A
Div Yield
—N/A
Momentum
50
52W High %
79%64.8
RS 6M
-27%35.1
SMA 50/200
0.98x51.0
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+90%71.6
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$172M
P/E (Forward)
-25.5x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MOLN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MOLN | Molecular Partners AG(you) | $172M | 19 | Strong Sell |
| SANN.SW | Santhera Pharmaceuticals Holding AG | $290M | 20 | Sell |
| ACIU | AC Immune SA | $299M | 13 | Strong Sell |
| OCS | Oculis Holding AG | $678M | 6 | Strong Sell |
| IDIA.SW | Idorsia Ltd | $1.7B | 22 | Sell |
| MLTX | MoonLake Immunotherapeutics | $1.3B | 8 | Strong Sell |
| PHVS | Pharvaris N.V. | $2.5B | 21 | Sell |
| CRSP | CRISPR Therapeutics AG | $5.6B | 20 | Sell |
| BANB.SW | Bachem Holding AG | $7.1B | 53 | Hold |
| BSLN.SW | Basilea Pharmaceutica AG | $986M | 97 | Strong Buy |
Peer medians: ROE 11.4% · P/E 29.9x · Gross margin 62.5%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.